According to Paratek Pharmaceuticals
's latest financial reports the company has $42.68 M in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2022-12-31 | $34.24 M | -64.13% |
2021-12-31 | $95.47 M | -23.72% |
2020-12-31 | $0.12 B | -41.89% |
2019-12-31 | $0.21 B | -26.45% |
2018-12-31 | $0.29 B | 93.01% |
2017-12-31 | $0.15 B | 18.5% |
2016-12-31 | $0.12 B | -2.49% |
2015-12-31 | $0.13 B | 36.98% |
2014-12-31 | $95.85 M | 36.85% |
2013-12-31 | $70.04 M | -17.86% |
2012-12-31 | $85.27 M | 36.74% |
2011-12-31 | $62.36 M | -8.25% |
2010-12-31 | $67.97 M | -23.54% |
2009-12-31 | $88.9 M | 4.47% |
2008-12-31 | $85.1 M | -10.05% |
2007-12-31 | $94.6 M | 46.5% |
2006-12-31 | $64.57 M | 27.82% |
2005-12-31 | $50.52 M | 8.32% |
2004-12-31 | $46.64 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Ultragenyx RARE | $0.57 B | 1,252.25% | ๐บ๐ธ USA |
Spectrum Pharmaceuticals
SPPI | $56.13 M | 31.51% | ๐บ๐ธ USA |
Agenus
AGEN | $76.11 M | 78.31% | ๐บ๐ธ USA |